<p><strong>Children</strong>:&nbsp;The safety and the efficacy of Cabazitaxel in children have not been established.<br />
<br />
<strong>Elderly</strong>:&nbsp;No specific dose adjustment for the use of Cabazitaxel in elderly patients is recommended (see Pharmacology: Pharmacokinetics under Actions, Precautions and Adverse Reactions).<br />
<br />
<strong>Hepatic Impairment</strong>:&nbsp;Cabazitaxel is extensively metabolized by the liver. Patients with mild hepatic impairment [total bilirubin &gt;1 to &le;1.5 x Upper Limit of Normal (ULN) or AST &gt;1.5 x ULN], should have cabazitaxel dose reduced to 20 mg/m2. Administration of cabazitaxel to patients with mild hepatic impairment should be undertaken with caution and close monitoring of safety. Limited efficacy data for cabazitaxel at 15 mg/m2, the maximum tolerated dose in patients with moderate hepatic impairment (total bilirubin &gt;1.5 to &le;3.0 x ULN), are available to recommend this dose in this population. Cabazitaxel should not be given to patients with severe hepatic impairment (total bilirubin &gt;3 x ULN).<br />
<br />
<strong>Renal Impairment</strong>:&nbsp;Cabazitaxel is minimally excreted through the kidney. No dose adjustment is necessary in patients with renal impairment not requiring hemodialysis. Patients presenting end-stage renal disease (CLCR&nbsp;&lt;15 mL/min/1.73 m2), by their condition and the limited amount of available data, therefore these patients should be treated with caution and monitored carefully during treatment.<br />
<br />
<strong>Concomitant Drug Use</strong>:&nbsp;Concomitant drugs that are strong CYP3A inducers or strong CYP3A inhibitors should be avoided (see Pharmacology: Pharmacokinetics under Actions and Interactions). However, if patients require co-administration of a strong CYP3A inhibitor, a 25% cabazitaxel dose reduction should be considered (see Pharmacology: Pharmacokinetics under Actions and Interactions).</p>